The same trial in the New England Journal of Medicine that showed a 15% weight loss found that weight tended to stop dropping and hold steady after 60 weeks, on average
And then there is diarrhea, with its unusual non-linear pattern: 1.64 at 4 mg, 2.51 at 8 mg, and 2.04 at 12 mg
Results of this study suggest a modest increase in the risk of NAION among individuals with type 2 diabetes associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association, the study concluded
#Pharmacovigilance #PatientSafety #ClinicalPharmacy #DrugSafety #HealthcareAwareness #ADRReporting #Semaglutide #GLP1 #DiabetesCare #WeightManagement #Pharma #HealthcareProfessionals #PvPI #MedicationSafety Semaglutide Adverse Reactions and Reporting **Adverse Drug Reactions Awareness: Semaglutide (GLP-1 Receptor Agonist)** Semaglutide has transformed the management of **Type 2 Diabetes** and **chronic weight management**, with added cardiovascular benefits
At 3 and 12 months post-index, 1.0 mg was the most common s.c